Targeting the frequently altered p53 signaling pathway in ALL, especially the main regulators of p53, MDM2, and CDKN2A, is a novel therapeutic strategy in anticancer drug discovery [19]. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.